Oncolytics Biotech
ONCY
56 hedge funds and large institutions have $3.77M invested in Oncolytics Biotech in 2025 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 10 increasing their positions, 7 reducing their positions, and 8 closing their positions.
228% more capital invested
Capital invested by funds: $1.15M → $3.77M (+$2.62M)
43% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 7
13% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 8
2% more funds holding
Funds holding: 55 → 56 (+1)
1.22% more ownership
Funds ownership: 1.59% → 2.81% (+1.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$428K |
| 2 |
Morgan Stanley
New York
|
+$408K |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$363K |
| 4 |
QC
Quadrature Capital
London,
United Kingdom
|
+$119K |
| 5 |
Goldman Sachs
New York
|
+$87.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
-$44.8K |
| 2 |
NDSI
Newman Dignan & Sheerar Inc
Providence,
Rhode Island
|
-$17.7K |
| 3 |
PCA
Prosperity Capital Advisors
Westlake,
Ohio
|
-$11.6K |
| 4 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
-$9.86K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$9.76K |
ONCY Hedge Fund Activity: Q3 2025 in Review
56 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Oncolytics Biotech (ONCY) for Q3 2025, worth a combined $3.77M — up 228% from $1.15M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new ONCY positions and 8 closed out — a net gain of 1 holder — while 10 added to existing stakes and 7 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $428K. The largest seller was Commonwealth Equity Services, cutting an estimated $44.8K.
- 56 institutional investors held Oncolytics Biotech (ONCY) as of Q3 2025, up from 55 in Q2 2025.
- Funds reported $3.77M of Oncolytics Biotech stock for Q3 2025, up 228% quarter-over-quarter.
- 9 funds opened new Oncolytics Biotech positions in Q3 2025 and 8 closed out, a net change of +1 holder.
- The largest Oncolytics Biotech buyer in Q3 2025 was Citadel Advisors, an estimated $428K added.
- The largest Oncolytics Biotech seller in Q3 2025 was Commonwealth Equity Services, an estimated $44.8K sold.
Based on aggregated 13F filings for Q3 2025.